These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24475233)

  • 1. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.
    Liu ZQ; Han YC; Zhang X; Chu L; Fang JM; Zhao HX; Chen YJ; Xu Q
    PLoS One; 2014; 9(1):e87103. PubMed ID: 24475233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
    Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
    Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
    Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
    Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
    Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
    Brandi G; Deserti M; Vasuri F; Farioli A; Degiovanni A; Palloni A; Frega G; Barbera MA; de Lorenzo S; Garajova I; Di Marco M; Pinna AD; Cescon M; Cucchetti A; Ercolani G; D'Errico-Grigioni A; Pantaleo MA; Biasco G; Tavolari S;
    Oncologist; 2016 May; 21(5):600-7. PubMed ID: 27032872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
    Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
    Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
    Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
    Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
    Nordh S; Ansari D; Andersson R
    World J Gastroenterol; 2014 Jul; 20(26):8482-90. PubMed ID: 25024604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
    Wei CH; Gorgan TR; Elashoff DA; Hines OJ; Farrell JJ; Donahue TR
    Pancreas; 2013 Nov; 42(8):1303-10. PubMed ID: 24152955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
    Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
    Br J Cancer; 2018 Apr; 118(7):947-954. PubMed ID: 29515256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
    Mohelnikova-Duchonova B; Melichar B
    Pancreatology; 2013; 13(6):558-63. PubMed ID: 24280569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
    Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
    Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
    Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
    Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; Mackey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW;
    J Natl Cancer Inst; 2014 Jan; 106(1):djt347. PubMed ID: 24301456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.